airexar spiromax
teva b.v. - salmeterol, flútikasón nef - pulmonary disease, chronic obstructive; asthma - lyf til veikindi öndunarvegi sjúkdómum, - airexar spiromax er ætlað til notkunar hjá fullorðnum 18 ára og eldri. asthmaairexar spiromax is indicated for the regular treatment of patients with severe asthma where use of a combination product (inhaled corticosteroid and long-acting β2 agonist) is appropriate:- patients not adequately controlled on a lower strength corticosteroid combination productor- patients already controlled on a high dose inhaled corticosteroid and long-acting β2 agonist. langvinn veikindi í lungum (llt)airexar viðeigandi er ætlað til meðferð við sjúklinga með llt, með fev1.
atomoxetin medical valley (atama) hart hylki 18 mg
medical valley invest ab - atomoxetinum hýdróklóríð - hart hylki - 18 mg
dolorin tafla 500 mg
williams & halls ehf - paracetamolum inn - tafla - 500 mg
atomoxetine stada hart hylki 60 mg
stada arzneimittel ag - atomoxetinum hýdróklóríð - hart hylki - 60 mg
paracet endaþarmsstíll 125 mg
karo pharma as - paracetamolum inn - endaþarmsstíll - 125 mg
atomoxetin medical valley (atama) hart hylki 10 mg
medical valley invest ab - atomoxetinum hýdróklóríð - hart hylki - 10 mg
atomoxetine stada hart hylki 40 mg
stada arzneimittel ag - atomoxetinum hýdróklóríð - hart hylki - 40 mg
paracet endaþarmsstíll 60 mg
karo pharma as - paracetamolum inn - endaþarmsstíll - 60 mg
atomoxetine stada hart hylki 10 mg
stada arzneimittel ag - atomoxetinum hýdróklóríð - hart hylki - 10 mg
estrumat vet. stungulyf, lausn 0,25 mg/ml
intervet international b.v.* - cloprostenolum natríum - stungulyf, lausn - 0,25 mg/ml